One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Liquidia now clears that threshold, with a jump from 72 to 88 Monday.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating of at least 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Liquidia is working on a consolidation with a 16.81 buy point. See if it can break out in volume at least 40% above average.
The company showed 0% earnings growth in the latest quarterly report. Revenue rose -36%. The company is expected to report its latest numbers on or around May 8.
Liquidia holds the No. 116 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
